Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Flutamide

FDA-approved product (capsule, oral), marketed as Eulexin, Flutamide.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Flutamide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Carcinoma
  • Metastatic prostate cancer
  • Neoplasm
  • Prostate adenocarcinoma
  • Prostate carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Anti-androgens
FDA pharmacologic class
Androgen Receptor Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA35.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli13.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae22.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis61.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Flutamide in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.7 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Flutamide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia

    NCT00001521 · start 1995-06-08

    Registered record
    Registry ID
    NCT00001521
    Conditions
    Congenital Adrenal Hyperplasia (CAH)
    Interventions
    Fludrocortisone; Hydrocortisone; Letrozole; Flutamide; Testolactone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1995-06-08
    Completion
    2024-04-01
    Enrolment
    66

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCongenital Adrenal Hyperplasia (CAH)
    InterventionFludrocortisone; Hydrocortisone; Letrozole; Flutamide +1 more
    PhasePhase 3
    Registry statusCompleted

  • Radiation Therapy and Hormone Therapy in Treating Patients With Prostate Cancer

    NCT00769548 · start 1995-04

    Registered record
    Registry ID
    NCT00769548
    Conditions
    Prostate Cancer
    Interventions
    flutamide; goserelin acetate; low-LET photon therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1995-04
    Completion
    2016-12
    Enrolment
    1,322

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    Interventionflutamide; goserelin acetate; low-LET photon therapy
    PhasePhase 3
    Registry statusCompleted

  • Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer

    NCT00002597 · start 1994-10

    Registered record
    Registry ID
    NCT00002597
    Conditions
    Prostate Cancer
    Interventions
    flutamide; Zoladex; Lupron; radiation therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1994-10
    Completion
    2018-05-14
    Enrolment
    2,028

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    Interventionflutamide; Zoladex; Lupron; radiation therapy
    PhasePhase 3
    Registry statusCompleted

  • A Phase II Trial of Leuprolide + Flutamide + Suramin in Untreated Poor Prognosis Prostate Carcinoma

    NCT00001266 · start 1990-10

    Registered record
    Registry ID
    NCT00001266
    Conditions
    Prostatic Neoplasm
    Interventions
    Suramin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1990-10
    Completion
    2003-08
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Neoplasm
    InterventionSuramin
    PhasePhase 2
    Registry statusCompleted

  • Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer

    NCT00003517

    Registered record
    Registry ID
    NCT00003517
    Conditions
    Adenocarcinoma of the Prostate; Stage III Prostate Cancer; Stage IV Prostate Cancer; Recurrent Prostate Cancer
    Interventions
    antineoplaston A10; antineoplaston AS2-1; bicalutamide; flutamide; leuprolide acetate; alternative product therapy; antiandrogen therapy; biological therapy; biologically based therapies; cancer prevention intervention; complementary and alternative therapy; differentiation therapy; endocrine therapy; hormone therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdenocarcinoma of the Prostate; Stage III Prostate Cancer; Stage IV Prostate Cancer; Recurrent Prostate Cancer
    Interventionantineoplaston A10; antineoplaston AS2-1; bicalutamide; flutamide +10 more
    PhasePhase 2
    Registry statusWithdrawn